You have 9 free searches left this month | to do more

derazantinib

Derazantinib is a drug used to treat Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma, and Gastric Adenocarcinoma. Derazantinib is being actively studied in 3 studies; no studies for this drug have been completed so far.

Top SponsorsTop SitesTop Investigators
Basilea PharmaceuticaBeatson West of Scotland Cancer Centre
Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestFondazione IRCCS Istituto Nazionale dei Tumori
Samsung Medical Center
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
I
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Bad Saarow, Germany
    HELIOS KLinikum Bad Saarow
2022-03-29
Mar 29, 2022
B
Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
Available
  • Intrahepatic Cholangiocarcinoma
  • derazantinib
  • (no location specified)
2021-06-17
Jun 17, 2021
B
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Combined Hepatocellular and Cholangiocarcinoma
  • derazantinib
  • Phoenix, Arizona
  • +40 more
2022-03-07
Mar 7, 2022
B
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
Recruiting
  • Gastric Adenocarcinoma
  • Derazantinib
  • +3 more
  • Gilbert, Arizona
  • +82 more
2022-03-07
Mar 7, 2022